Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Capricor's Duchenne drug gets three-month FDA extension after new data submission

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

The FDA has extended its review of Capricor Therapeutics' experimental cell therapy for Duchenne muscular dystrophy by three months to November 22, allowing more time to assess new clinical trial data submitted by the company.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 14 Aug 2026 and 24 Aug 2026.

◆ ◆ The Wire takeaway

You have a rare opportunity to engage with the Duchenne drug market as regulatory delays open more time to align your clinical data with FDA expectations. This pause highlights that trial evidence will be decisive for therapy approval and market positioning.

◆ Coverage

4 sources · first reported 14 Aug 2026 · latest 24 Aug 2026

◆ Related on Wire

◆ Topics

BiotechFDAdrug-approvalduchenne-muscular-dystrophyclinical-trialscell-therapy